|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.54 USD | -0.42% |
|
-3.18% | -27.56% |
| 05-15 | Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director | CI |
| 05-12 | Collegium completes acquisition of Azstarys® from Corium Therapeutics | RE |
Company Valuation: Collegium Pharmaceutical, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,088 | - | - |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -25.67% | - | - |
| Enterprise Value (EV) 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,839 | 1,416 | 1,088 |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | 25.63% | -23.01% | -23.15% |
| P/E | 10x | -31.4x | 23.9x | 15.4x | 26.8x | 12.6x | 8.99x | - |
| PBR | - | - | - | - | - | 3.07x | 2.17x | - |
| PEG | - | 0x | -0x | 0.3x | -3.83x | 0.2x | 0.2x | - |
| Capitalization / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 1.24x | 1.23x | 1.3x |
| EV / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 2.1x | 1.6x | 1.3x |
| EV / EBITDA | 5.49x | 2.93x | 2.74x | 2.3x | 3.18x | 3.8x | 3.08x | 2.58x |
| EV / EBIT | 36.9x | 23.4x | 6.01x | 5.44x | 8.15x | 3.88x | 3.26x | 2.79x |
| EV / FCF | - | - | 3.66x | 4.54x | 4.47x | 5.84x | 3.36x | - |
| FCF Yield | - | - | 27.3% | 22% | 22.4% | 17.1% | 29.7% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 | 2.66 | 3.73 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 276.9 | 463.9 | 566.8 | 631.4 | 780.6 | 874.6 | 885.9 | 833.9 |
| EBITDA 1 | 118.3 | 266 | 367 | 401.2 | 460.5 | 484.1 | 460.1 | 422.1 |
| EBIT 1 | 17.63 | 33.32 | 167 | 169.9 | 179.6 | 474.5 | 434.5 | 389.7 |
| Net income 1 | 71.52 | -25 | 48.16 | 69.19 | 62.87 | 108.2 | 158.3 | - |
| Net Debt 1 | - | - | - | - | - | 750.9 | 327.7 | - |
| Reference price 2 | 18.68 | 23.20 | 30.78 | 28.65 | 46.30 | 33.54 | 33.54 | 33.54 |
| Nbr of stocks (in thousands) | 34,797 | 33,572 | 32,611 | 32,250 | 31,611 | 32,434 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 2/22/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.61x | 2.1x | 3.8x | - | 1.09B | |
| 32.01x | 11.69x | 23.99x | 0.62% | 980B | |
| 24.41x | 5.63x | 15.32x | 2.34% | 550B | |
| 26.86x | 6.49x | 13.28x | 3.17% | 382B | |
| 17.04x | 4.24x | 10.43x | 3.13% | 316B | |
| 21.94x | 4.59x | 13.02x | 1.91% | 272B | |
| 20.28x | 5.27x | 12.78x | 3.05% | 268B | |
| 13x | 4.83x | 9.94x | 3.87% | 199B | |
| 21.95x | 5.91x | 10.33x | 2.99% | 182B | |
| -44.34x | 5.36x | 29.54x | 2.62% | 154B | |
| Average | 14.58x | 5.61x | 14.24x | 2.63% | 330.34B | |
| Weighted average by Cap. | 21.68x | 7.23x | 16.85x | 2.17% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- COLL Stock
- Valuation Collegium Pharmaceutical, Inc.
Select your edition
All financial news and data tailored to specific country editions
